Clinigen Group, the global pharmaceutical and services company, has appointed Terry Walsh as Senior VP of Clinical Trials Services. The company has also promoted Benjamin Miny, the former Managing Director of Clinigen South Africa, to Senior VP of Commercial Medicines.
Clinigen Clinical Trials Services is a specialist in the supply and management of quality-assured comparator medicines, and services to clinical trials and investigator initiated trials (IIT).
Walsh has been appointed with the aim of better positioning and strengthening the CTS business in the US, aiming to drive the future development of the business globally.
The priorities are to further develop the expanded services, formalise the IIT service offering, increase client penetration and extend into new markets.
Walsh joins from GSK where he held a number of senior leadership roles in Clinical Trial Supply Chain, Outsourcing and External Drug Discovery, US Managed Markets and Comparator Management.
Whilst at GSK, he worked with TransCelerate Biopharma, the not-for-profit pharma industry collaboration organisation, where he created the Comparator Purchasing Network. Walsh is considered an industry-wide expert in comparator sourcing strategies. He will join Clinigen on 19 March 2018.
Benjamin Miny's role will include both the global management of Clinigen’s Commercial Medicines division and the strategic development of the Group’s unlicensed to licenced strategy.
This has already proved successful in South Africa, with Clinigen launching Eisai products and following the acquisition of Quantum Pharma in 2017, Clinigen seeks to expand these capabilities further.
Shaun Chilton, Group CEO of Clinigen, said: “Terry brings extensive industry experience to the team which will allow us to strengthen the CTS business in the US and drive the global business strategy to capitalise on the rapidly developing and competitive market. With our clients demanding ever more global and complex solutions, we aim to maintain our position as a trusted partner capable of delivering high quality service. We look forward to welcoming Terry to the team.”
“Benjamin’s promotion demonstrates what an invaluable contribution he has made to date, using his expertise in the Africa and Asia Pacific markets gained whilst working for the Link business.”
It also marks the first promotion to the senior management team of a former Link employee following its acquisition in 2015. This demonstrates the importance of these geographic markets to the Group and the strategic significance of licenced medicines to Clinigen as a whole.”